Kliniken für Mutter-Kind-Gesundheit

Abstrakt

Commentary on a "Strategy to Develop Clinical Peptide Biomarkers for MoreAccurate Evaluation of the Pathophysiological Status of Hypertensive Disordersof Pregnancy"

Yoshihiko Araki*

Hypertensive disorders of pregnancy (HDP) are serious complications of pregnancy.　Many studies have sought to identify candidate disease biomarkers (DBMs) for use in clinical testing. Accumulating evidence suggests that many proteolytic peptides associated with individual health conditions are present in human body fluids, including peripheral blood. Here, the potential utility of peptidomic analysis for monitoring the pathogenesis of HDP is introduced and described. In particular, the importance of understanding the current technical limitations of the methods used to discover DBM in the blood is emphasized.